Abstract:Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate (12%) and is predicted to become the second leading cause of cancer related deaths by 2030. The main treatment option for advanced PDAC, gemcitabine (GEM) and nab-paclitaxel (PAC) chemotherapy, has limited efficacy due to adverse toxicities and chemoresistance. Extensive desmoplasia in the PDAC microenvironment induces hypoxia that drives epithelial to mesenchymal transition (EMT) and promotes cancer stem cells (CSCs) leading to metastasis and acquired resistance. Drugs that target CSCs and EMT to overcome chemoresistance could improve patient outcome. Disulfiram (DSF), an FDA approved anti alcoholism drug, has excellent anticancer activity on chelation with Cu2+/Zn2+ ions to form the anticancer metabolites, Copper or Zinc Diethyldithiocarbamate (CuDDC or ZnDDC). The anticancer application of the current oral version of DSF is prevented by its short plasma half-life ( 4 months) to increasing doses of each drug (DSF-Cu, Alb-CuDDC and Alb-ZnDDC), PANC1 and BXPC3 PDAC cells acquired resistance only to Alb-ZnDDC. PANC1ZR6 and BXPC3ZR5 resistant cells showed increased expression of CSC markers and significant cross-resistance to PAC and GEM suggesting multidrug resistance. Importantly, no cross-resistance to Alb-CuDDC or DSF-Cu was observed, suggesting alternative mechanisms for Alb-ZnDDC. RNA sequencing is underway to identify potential mechanisms involved. To conclude, albumin formulation improved the solubility and stability of DSF-metal complexes. Alb-CuDDC targets CSCs and overcomes resistance in PDAC, similar to free DSF-Cu. Alb-ZnDDC may have alternative mechanisms which are yet to be elucidated. Citation Format: Benjamin J. Small, Ogechi Nkeonye, Vinodh Kannappan, Shalini Kumarasamy, Kate Butcher, Karim Azar, Gowtham Rajendran, Yoshitha Lakshmanan Lakshmanan, Mark Morris, Christopher Heeschen, Yaohe Wang, Weiguang Wang. Disulfiram and its metal complexes reversed hypoxia induced stemness and synergized with first line drugs in primary patient derived pancreatic ductal adenocarcinoma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5877.

Supplementary Figure from PLGA–Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma <i>in Vitro</i> and <i>in Vivo</i>

Data from PLGA–Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma <i>In Vitro</i> and <i>In Vivo</i>

Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or Without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy

Supplementary Figure from IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment

Supplementary Figures 6-7 from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Supplementary Figure Legends 1-4 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplemental Methods from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Supplementary Figure 1 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin Via Reactive Oxygen Species Modulation

Anti-alcoholism drug disulfiram for targeting glioma energy metabolism using BBB-penetrating delivery of fixed-dose combination

Disulfiram, a Ferroptosis Inducer, Triggers Lysosomal Membrane Permeabilization by Up-Regulating ROS in Glioblastoma

Abstract 5877: Disulfiram and its metal complexes reversed hypoxia induced stemness and synergized with first line drugs in primary patient derived pancreatic ductal adenocarcinoma cells

Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Supplemental Figures W/ Legends from Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition

Supplementary Figure 1 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Therapeutic effect of disulfiram inclusion complex embedded in hydroxypropyl-β-cyclodextrin on intracranial glioma-bearing male rats via intranasal route

Supplementary Figures 4 - 8 from Arylsulfonamide KCN1 Inhibits in Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors P300/cbp

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Expression of concern: A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma

Biomimetic Nanoarchitectonics with Chitosan Nanogels for Collaborative Induction of Ferroptosis and Anticancer Immunity for Cancer Therapy

Supplementary Figure from PLGA–Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma &lt;i&gt;in Vitro&lt;/i&gt; and &lt;i&gt;in Vivo&lt;/i&gt;